Last 11 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -11.25 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | 18.48 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 3.12 | 4.68 | 3.13 | 2.94 | 2.20 | 1.53 | 0.68 | 1.12 | 1.22 | 1.39 | — | — |
| — | +205.8% | +363.1% | +162.5% | +81.2% | +10.1% | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | -121.1% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | -99.3% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -28.2% | -12.7% | -4.2% | -6.8% | -6.9% | -9.7% | -8.1% | -6.4% | -5.3% | -12.2% | — | — |
| — | -30.1% | +49.0% | -6.6% | -30.7% | +20.2% | — | — | — | — | — | — | |
| ROA | -26.9% | -11.8% | -3.9% | -6.4% | -6.6% | -9.1% | -7.8% | -6.2% | -5.2% | -6.6% | -12.5% | -8.7% |
| — | -30.1% | +49.6% | -4.2% | -26.7% | -38.7% | +37.8% | +28.9% | — | — | — | — | |
| ROIC | -27.1% | -11.8% | -4.3% | -8.1% | -9.1% | -9.7% | -8.4% | -6.6% | -6.3% | -26.8% | — | — |
| — | -21.6% | +48.8% | -22.5% | -44.6% | +63.8% | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.05 | 0.03 | 0.00 | 0.01 | 0.01 | — | — |
| — | -46.9% | -16.5% | +390.3% | +354.1% | +733.4% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 26.17 | 15.72 | 27.08 | 26.17 | 36.37 | 22.75 | 31.01 | 35.34 | 45.91 | 42.08 | 20.10 | 17.14 |
| — | -30.9% | -12.7% | -25.9% | -20.8% | -45.9% | +54.2% | +106.2% | — | — | — | — | |
| Quick Ratio | 26.17 | 15.72 | 27.08 | 26.17 | 36.37 | 22.75 | 31.01 | 35.34 | 45.91 | 42.08 | 20.10 | 17.14 |
| — | -30.9% | -12.7% | -25.9% | -20.8% | -45.9% | +54.2% | +106.2% | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 11 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RAPP stock.
Rapport Therapeutics, Inc. Common Stock's current P/E is -11.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Rapport Therapeutics, Inc. Common Stock's business trajectory between earnings reports.